Actively Recruiting

Age: 3Years +
All Genders
ID07628946

Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy

Led by Dan Chen · Updated on 2026-06-05

3000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting an observational study to explore the links between common blinding retinal diseases like diabetic retinopathy, pathological myopia, and age-related macular degeneration, and changes in the fine structures of the front part of the eye. The study aims to understand these connections deeply by collecting detailed data using advanced imaging technologies. The goal is to build a comprehensive eye image database that could help identify early warning signs and support future AI-assisted diagnosis and treatment models. Participants will undergo multimodal imaging of both the eye surface and the retina using technologies such as Ultra-Widefield fundus photography, OCT/OCTA, adaptive optics scanning laser ophthalmoscopy, corneal confocal microscopy, and tests assessing meibomian gland function, corneal sensitivity, and tear film function. Participants will be grouped based on inflammatory-related ocular diseases or non-inflammatory-related ocular diseases, with data collected at baseline and within 30 days post-examination. During the study, participants will have their eye condition assessed through multiple measures including tear break-up time, dry eye questionnaires, blink rate, lipid layer thickness, and tear meniscus height, along with retinal thickness and fluid presence. Medical records and follow-up information will be collected to support analyses. The study will monitor these parameters carefully to build a standardized database to aid diagnostics. Participation may last up to several months depending on follow-up availability.

CONDITIONS

Brief Title

Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy

Who Can Participate

Age: 3Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with retinal vascular or metabolic diseases such as diabetic retinopathy, retinal vein occlusion, or hypertensive retinopathy
  • Diagnosed with degenerative diseases like age-related macular degeneration, pathological myopia, or polypoidal choroidal vasculopathy
  • Diagnosed with immune-mediated or inflammatory eye diseases including uveitis, optic neuritis, Mooren's ulcer, or corneal melting linked to systemic immune diseases
  • Diagnosed with anterior segment and ocular surface syndromes such as dry eye disease, keratoconus, or glaucoma with chronic inflammation or long-term medication use
  • Diagnosed with developmental fundus diseases in children or adolescents including Coats' disease, familial exudative vitreoretinopathy, or retinopathy of prematurity
  • Confirmed diagnosis of fundus diseases like diabetic retinopathy, pathological myopia, or age-related macular degeneration
  • Able to cooperate with advanced eye examinations and imaging techniques with acceptable image quality
  • Availability of complete or accessible ophthalmic medical records
  • Blood pressure less than or equal to 160/100 mmHg
Not Eligible

You will not qualify if you...

  • Recent corneal or conjunctival acute inflammation, ocular surgery, or trauma within the past 3 months
  • Presence of corneal changes such as those caused by contact lens wear
  • Fundus images that are unclear or severely obscured, such as from vitreous hemorrhage
  • Use of medications affecting tear secretion (like antihistamines or antidepressants) within the past 30 days

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Within 30 days

Participants undergo advanced eye examinations and imaging techniques to collect detailed ophthalmic data.

1 to 2 visits depending on eye examinations

Long-term Monitoring

Duration - Up to the study completion date

Participants are observed to monitor inflammation-related ophthalmopathy through collected imaging and clinical data.

Visits as needed for imaging and assessments

Trial Site Locations

Total: 1 location

1

Beijing Tongren Hospital

Beijing, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and ...

Inflammatory Disease

Actively Recruiting

1 location

Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Deciphe...

Rheumatoid Arthritis

Actively Recruiting

1 location

Randomized, Double-blind Study Comparing Ranibizumab 10mg/ml...

Diabetic Macular Edema

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here